Trials / Completed
CompletedNCT01913730
Maintenance Therapy With Subcutaneous Bortezomib
A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SC BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- European Myeloma Network B.V. · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, open label study designed to evaluate the efficacy and safety of prolonged treatment with bortezomib twice monthly and dexamethasone after a salvage treatment containing bortezomib for relapsed or refractory multiple myeloma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib | |
| DRUG | Dexamethasone |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2021-04-01
- Completion
- 2023-09-07
- First posted
- 2013-08-01
- Last updated
- 2023-12-13
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01913730. Inclusion in this directory is not an endorsement.